Overactive Bladder Treatment Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

 

Overactive Bladder Treatment Market

Overactive Bladder (OAB) is a group of symptoms that includes frequent urination, a strong need to urinate, urine leakage, and the need to urinate at least twice every night. OAB is categorised as a condition rather than a disease. Numerous factors, including weak pelvic muscles, nerve damage from trauma or disease, urinary tract infections (UTI), obesity, hormonal imbalance after menopause, drugs, caffeine, and alcohol, can cause an overactive bladder. Among the illnesses that cause an overactive bladder include Parkinson's disease, Multiple Sclerosis, and stroke. Therapy options for overactive bladder include medication, surgery, Botox bladder treatment, as well as some behavioural modifications such diet adjustments and bladder retraining.

The main factors driving expansion for Overactive Bladder Treatment Market are an increase in the elderly population and growing knowledge about treatments for overactive bladder syndrome. For instance, 1 in 3 persons over the age of 30 worldwide experienced nocturia in 2018, according to the National Association for Continence. Additionally, about 25 million Americans experienced urine incontinence in 2018, according to a data released by the U.S. Department of Health & Human Services.

The Overactive Bladder Treatment Market is anticipated to be significantly impacted by COVID-19. This is mainly because COVID-19 recovered patients are seeing an increase in overactive bladder symptoms. Ten to fourteen weeks after being hospitalised with COVID-19, individuals are reported to have de novo or increasing overactive bladder symptoms, according to the study "Long COVID and COVID-19 Associated Cystitis (CAC)" published in November 2021. Furthermore, the study "COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC)" published in December 2020 noted that COVID-19 inflammation caused urine cytokine elevation, which increased urination frequency and resulted in overactive bladder disorder in COVID-19-infected patients.

In addition, the rising geriatric population and the rising incidence of diseases like Parkinson's disease, which causes overactive bladder disorder, are the main factors driving the Global Overactive Bladder Treatment Market. For instance, the World Population Prospect estimates that there will be 771 million seniors worldwide in 2022, and that number will rise to 994 million by 2030 and 1.6 billion by 2050. Since urinary incontinence typically worsens as people age, an overactive bladder has a significant detrimental effect on the health and quality of life of the elderly population.

Top Companies Mentioned are- Pfizer Inc., Johnson & Johnson, Aurobindo Pharma Ltd., Astellas Pharma Inc., Merck & Co. Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Allergan, AbbVie Inc., Sanofi, Cogentix Medical and Endo International Plc.

Comments

Popular posts from this blog

Ginseng Market Outlook, Analysis and forecast up to 2028

Forging has significant application in creation of various metal for wide range of applications

The Vaccine Contract Manufacturing Industry to Flourish Due to Urgent Need to Develop Reliable and Cost-Effective Vaccines against Covid-19